Neurosteroid binding to the amino terminal and glutamate binding domains of ionotropic glutamate receptors

• Published in: Steroids 2012-06, Vol.77 (7), p.774-779
• Main Authors: Cameron, Krasnodara, Bartle, Emily, Roark, Ryan, Fanelli, David, Pham, Melissa, Pollard, Beth, Borkowski, Brian, Rhoads, Sarah, Kim, Joon, Rocha, Monica, Kahlson, Martha, Kangala, Melinda, Gentile, Lisa
• Format: Article
• Language: English
• Subjects: Amino terminal domain; Binding Sites; Biological and medical sciences; Cloning, Molecular; Fundamental and applied biological sciences. Psychology; iGluR; Models, Molecular; Neurotransmitter Agents - metabolism; Pregnanolone - analogs & derivatives; Pregnanolone - metabolism; Pregnanolone sulfate; Pregnenolone - metabolism; Pregnenolone sulfate; Receptors, Ionotropic Glutamate - chemistry; Receptors, Ionotropic Glutamate - genetics; Receptors, Ionotropic Glutamate - metabolism; Spectrometry, Fluorescence; Vertebrates: endocrinology
• ISSN: 0039-128X; 1878-5867
• DOI: 10.1016/j.steroids.2012.03.011

► PS and PREGAS bind primarily in the S1S2 domain of the NMDA GluN2B subunit. ► PS and PREGAS bind in the amino terminal domain of the NMDA GluN2D subunit. ► PS and PREGAS bind in both the ATD and S1S2 domain of the AMPA GluA2 subunit. ► NMDA and non-NMDA iGluRs may be negatively regulated by neurosteroids differently. ► PS and PREGAS are the first reported ligands to bind to the GluA2 ATD. The endogenous neurosteroids, pregnenolone sulfate (PS) and 3α-hydroxy-5β-pregnan-20-one sulfate (PREGAS), have been shown to differentially regulate the ionotropic glutamate receptor (iGluR) family of ligand-gated ion channels. Upon binding to these receptors, PREGAS decreases current flow through the channels. Upon binding to non-NMDA or NMDA receptors containing an GluN2C or GluN2D subunit, PS also decreases current flow through the channels, however, upon binding to NMDA receptors containing an GluN2A or GluN2B subunit, flow through the channels increases. To begin to understand this differential regulation, we have cloned the S1S2 and amino terminal domains (ATD) of the NMDA GluN2B and GluN2D and AMPA GluA2 subunits. Here we present results that show that PS and PREGAS bind to different sites in the ATD of the GluA2 subunit, which when combined with previous results from our lab, now identifies two binding domains for each neurosteroid. We also show both neurosteroids bind only to the ATD of the GluN2D subunit, suggesting that this binding is distinct from that of the AMPA GluA2 subunit, with both leading to iGluR inhibition. Finally, we provide evidence that both PS and PREGAS bind to the S1S2 domain of the NMDA GluN2B subunit. Neurosteroid binding to the S1S2 domain of NMDA subunits responsible for potentiation of iGluRs and to the ATD of NMDA subunits responsible for inhibition of iGluRs, provides an interesting option for therapeutic design.